Document is current
Any future updates will be listed below
-
Authors
Dhaliwal, Deepinder K.
Shukla, Aakriti Garg
Paul Singh, I.
Syed, Zeba A.
White, Darrell E.
-
Funding
Funding for this research was provided by:
Thea Pharmaceuticals
- License Information
-
More Information
Article History
Received: 5 August 2025
Accepted: 28 August 2025
First Online: 19 September 2025
Declarations
:
: Deepinder K. Dhaliwal: Consultant/Advisor: Thea, Bausch + Lomb, Johnson & Johnson, Staar Surgical, Aurion Biotech, Scope Eyecare, Tarsus, CSI Dry Eye Software, Epion Therapeutics, Lenz Therapeutics, and EyeYon Medical. Research grants: Bausch + Lomb, Epion Therapeutics, Kala. Aakrita G. Shukla: Consultant/Speaker: Alcon; Consultant: Thea; Consultant: AbbVie. Paul Singh: Consultant: Allergan, Alcon, Bausch + Lomb, Glaukos, iSTAR Medical, New World Medical, Nova Eye Medical, and Sight Sciences; Lecture fees: Allergan, Alcon, Bausch + Lomb, Glaukos, iSTAR Medical, New World Medical, Nova Eye Medical, Sight Sciences, Thea, and Viatris. Zeba A. Syed: nothing to disclose. Darrell E. White: Consultant: Aldeyra Therapeutics; Speaker/Consultant: Allergan/AbbVie; Speaker/Consultant: Bausch + Lomb; Consultant: Bruder; Speaker/Consultant: Viatris/Oyster Point Pharma; Speaker/Consultant: Sun Ophthalmics; Consultant: Tarsus; Speaker/Consultant/ Investor: Orasis Pharmaceuticals: Speaker/Consultant: Nordic Pharma; Consultant/Investor: SpyGlass Pharma.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
